Table 1.
The study characteristics and quality assessment of 25 included papers in this systematic review.
| Author | Publication Year | Study Period | Study Region | Total Positive Samples | Percentage * (%) | MDR | Folp1 (n/%) | RpoB (n/%) | GyrA (n/%) | JBI Scores |
|---|---|---|---|---|---|---|---|---|---|---|
| Charlotte et al. [19]. | 2016 | 2012–2015 | Africa | 24 | 100.00 | 0 | 3 (12.50) | 1 (4.17) | 0 (0.00) | 6 |
| Masanori et al. [20]. | 2011 | 2004–2009 | Asia | 290 | 68.56 | 0 | 19 (10.16) | 7 (4.29) | 0 (0.00) | 6 |
| Adalgiza et al. [21]. | 2012 | 2006–2008 | South America | 145 | 100.00 | 3 | 3 (5.26) | 4 (7.02) | 2 (3.51) | 7 |
| Liu et al. [22]. | 2015 | 2007–2014 | Asia | 85 | 100.00 | 3 | 1 (1.49) | 5 (8.77) | 21 (31.34) | 6 |
| Williams et al. [23]. | 2013 | 2011–2012 | North America | 39 | 100.00 | 0 | 2 (5.13) | 1 (2.56) | 0 (0.00) | 6 |
| Mallika, et al [24]. | 2014 | 2009–2013 | Asia | 111 | 79.29 | 2 | 9 (8.11) | 4 (3.60) | 9 (9.01) | 6 |
| Rosa et al. [25]. | 2020 | 2009–2013 | South America | 37 | 100.00 | 12 | 16 (59.26) | 15 (60.00) | 2 (7.41) | 6 |
| Lavania, et al. [26]. | 2015 | 2013–2014 | Asia | 215 | 93.02 | 0 | 1 (0.47) | 7 (3.26) | 0 (0.00) | 7 |
| Narang et al. [27]. | 2021 | 2019–2020 | Asia | 61 | 100.00 | 2 | 5 (8.20) | 6 (9.84) | 1 (1.64) | 7 |
| Niranjan et al. [28]. | 2020 | 2007–2018 | Asia | 77 | 92.77 | 2 | 2 (2.60) | 1 (1.30) | 5 (6.49) | 6 |
| Martha, et al [29]. | 2014 | 1985–2004 | South America | 941 | 100.00 | 6 | 4 (0.43) | 27 (2.87) | 10 (1.38) | 6 |
| Camilo et al. [30]. | 2016 | 2004–2013 | South America | 243 | 100.00 | 1 | 5 (2.06) | 5 (2.06) | 1 (0.41) | 6 |
| Lavania et al. [14]. | 2018 | 2009–2016 | Asia | 250 | 100.00 | 17 | 16 (6.40) | 11 (4.40) | 10 (4.00) | 6 |
| Chokkakula et al. [31]. | 2019 | 2013–2017 | Asia | 290 | 100.00 | 2 | 8 (2.76) | 1 (0.34) | 8 (2.76) | 6 |
| You et al. [32]. | 2005 | NR | Asia | 104 | 100.00 | 5 | 20 (19.23) | 3 (2.88) | 1 (0.96) | 6 |
| Chen et al. [33]. | 2019 | 2003–2011 | Asia | 76 | 100.00 | 1 | 19 (25.00) | 0 (0.00) | 1 (1.32) | 7 |
| Masanori et al. [34]. | 2010 | NR | North America | 38 | 100.00 | 0 | 0 (0.00) | 2 (5.26) | 1 (2.63) | 6 |
| Chauffour et al. [35]. | 2018 | 2001–2015 | Europe | 160 | 86.96 | 0 | 13 (8.13) | 3 (1.88) | 2 (1.25) | 6 |
| Singh et al. [36]. | 2018 | NR | Asia | 78 | 84.78 | 0 | 0 (0.00) | 0 (0.00) | 8 (32.00) | 7 |
| Masanori et al. [37]. | 2007 | 2000–2006 | Asia | 305 | 100.00 | 0 | 6 (4.58) | 9 (11.54) | 0 (0.00) | 6 |
| Matilde et al. [38]. | 2014 | 2009–2011 | South America | 197 | 100.00 | 1 | 0 (0.00) | 4 (5.26) | 0 (0.00) | 5 |
| Singh et al. [39]. | 2011 | NR | South America | 233 | 100.00 | 0 | 2 (0.86) | 1 (0.43) | 0 (0.00) | 7 |
| Abu et al. [40]. | 2015 | 2007–2009 | Asia | 50 | 100.00 | NS | NS | 2 (4.00) | NS | 6 |
| Sundeep et al. [41]. | 2014 | NR | Asia | 60 | 100.00 | NS | NS | 10 (16.67) | NS | 6 |
| Shi et al. [42]. | 2022 | 2018–2021 | Asia | 34 | 100.00 | 1 (3.13) | 0 (0.00) | 3.13 | 6 |
%: Positive Sample; NS: Not studied; MB: Multibacillary; PB: Paucibacillary. *: Percentage of positive samples out of all samples.